Integrating MRD kinetics with allogeneic SCT decisions in AML.
作者信息
Jen Wei-Ying, Short Nicholas J
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Blood Adv. 2025 Aug 12;9(15):4065-4066. doi: 10.1182/bloodadvances.2025016766.
Abstract
摘要
相似文献
1
Integrating MRD kinetics with allogeneic SCT decisions in AML.将微小残留病动力学与急性髓系白血病的异基因造血干细胞移植决策相结合。
Blood Adv. 2025 Aug 12;9(15):4065-4066. doi: 10.1182/bloodadvances.2025016766.
2
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.首次完全缓解的急性髓系白血病患者的异基因干细胞移植：前瞻性临床试验的系统评价和荟萃分析
JAMA. 2009 Jun 10;301(22):2349-61. doi: 10.1001/jama.2009.813.
3
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.FLT3-ITD阳性急性髓系白血病的预后：异基因干细胞移植和酪氨酸激酶抑制剂治疗的影响
J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24.
4
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.WT1基因表达检测在细胞完全缓解后接受异基因干细胞移植的急性髓系白血病患者中对移植前微小残留病检测具有较高的预后价值。
Leuk Res. 2017 Dec;63:22-27. doi: 10.1016/j.leukres.2017.10.010. Epub 2017 Oct 27.
5
Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes.患者中危急性髓系白血病的可测量残留病与首次缓解、治疗和结局的相关性。
JAMA Netw Open. 2021 Jul 1;4(7):e2115991. doi: 10.1001/jamanetworkopen.2021.15991.
6
Role of WT1 in Measurable Residual Disease Follow-Up in the Post Allogeneic Stem Cell Transplant Setting.WT1在异基因造血干细胞移植后可测量残留病随访中的作用。
J Clin Med. 2024 Aug 30;13(17):5145. doi: 10.3390/jcm13175145.
7
Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.干细胞移植治疗急性白血病的临床效果和成本效益：系统评价。
Health Technol Assess. 2010 Dec;14(54):iii-iv, ix-xi, 1-141. doi: 10.3310/hta14540.
8
9
Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.急性髓系白血病患者异基因干细胞移植后微小残留病阳性的移植前危险因素：一项前瞻性研究。
Bone Marrow Transplant. 2025 Mar;60(3):277-285. doi: 10.1038/s41409-024-02466-1. Epub 2024 Nov 16.
10
Association of Persistent Minimal Residual Disease with Poor Outcomes of Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.异基因造血干细胞移植治疗急性髓系白血病患者微小残留病持续存在与不良预后的相关性。
Chin Med J (Engl). 2018 Dec 5;131(23):2808-2816. doi: 10.4103/0366-6999.246072.
本文引用的文献
1
Frontline allo-SCT in MRD-negative, intermediate-risk AML.微小残留病阴性、中危急性髓系白血病的一线异基因造血干细胞移植
Blood Adv. 2025 Aug 12;9(15):4063-4064. doi: 10.1182/bloodadvances.2025016610.
2
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.维奈托克联合FLAG-IDA诱导和巩固治疗新诊断、复发或难治性急性髓系白血病的长期结果
Leukemia. 2025 Apr;39(4):854-863. doi: 10.1038/s41375-025-02531-8. Epub 2025 Feb 25.
3
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy.接受强化化疗的急性髓系白血病患者中可测量残留病清除动力学的影响
Blood Adv. 2025 Feb 25;9(4):783-792. doi: 10.1182/bloodadvances.2024013826.
4
Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.NPM1 突变型 AML 的分子、临床和治疗学决定因素。
Blood. 2024 Aug 15;144(7):714-728. doi: 10.1182/blood.2024024310.
5
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of .吉特替尼作为伴有. 内部串联重复突变的 AML 移植后维持治疗。
J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12.
6
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.诱导后分子 MRD 可识别出 NPM1 AML 患者在首次缓解期时从同种异体移植中获益。
Blood. 2024 May 9;143(19):1931-1936. doi: 10.1182/blood.2023023096.
7
Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial.异基因造血细胞移植与标准强化化疗治疗中危急性髓系白血病患者的随机临床试验。
JAMA Oncol. 2023 Apr 1;9(4):519-526. doi: 10.1001/jamaoncol.2022.7605.
Zotero 插件